Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S018000
Reexamination Certificate
active
07049321
ABSTRACT:
There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more Spiro compounds. Also provided and pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.
REFERENCES:
patent: 3897425 (1975-07-01), Bodor et al.
patent: 4855290 (1989-08-01), Fisher et al.
patent: 4876260 (1989-10-01), Fisher et al.
patent: 4900830 (1990-02-01), Fisher et al.
patent: 4981858 (1991-01-01), Fisher et al.
patent: 5053412 (1991-10-01), Fisher et al.
patent: 5407938 (1995-04-01), Fisher et al.
patent: 5534520 (1996-07-01), Fisher et al.
patent: 5852029 (1998-12-01), Fisher et al.
patent: 6274603 (2001-08-01), Poirier
patent: 6277874 (2001-08-01), Crutcher et al.
patent: 1 203 430 (1970-08-01), None
patent: WO 8503866 (1985-09-01), None
English Abstract Caplus DN 102:226107 Matsuda Rieko et al 1985.
English Abstract Caplus DN 86:139325, Kaminski, et al 1976 vol. 65, Isuue 12, pp. 1733-1737.
English Abstract, Caplus DN 75:20377 Nakanishi, et al 1971 vol. 91 Isuue 3, pp. 363-383.
Fisher and Barak, Drug News & Perspectives 7:453-64, 1994.
Review: Fisher. jap J Pharmacol 84: 101-112, 2000.
Wolozin et al. Arch Neurol. 57:1439-43, 2000.
Sparks et al. Neurosci Lett 187:142-144, 1995.
Refolo et al. Soc Neurosci Abst, San Diego, CA, USA, 2001.
Refolo et al. Neurobiol Dis 8: 890-899, 2001.
Review: Cedazo-Minguez and Cowburn. J Cell Mol Med 5:254-266, 2001.
Bales et al. PNAS 96: 15233, 1999.
Buttini et al. Neurosci 97: 207, 2000.
Hartmann et al, Exp Neurol 170: 326, 2001.
Mudher and Lovestone. Trends Neurosci 25:22-6, 2002.
Mudher et al. J Neurosci 21:4987-95, 2001.
Zhang et al. Nature 395: 698-702, 1998.
De Ferrari et al. Brain Res Brain Res Rev 33:1-12, 2000.
Garrido et al. FASEB J 16:1982-4, 2002.
Eldar-Finkelman. Trends Molec Med. 8:126-32, 2002.
Bhat et al. Neurosignals 11:251-61, 2002.
Gentleman et al. NeuroReport 8: 1519-1522, 1997.
Roberts et al. J Neurol Neurosurg Psychiat, 57: 419-425, 1994.
Havlik et al. Neurobiol Aging S140, 587, 1998.
Mayeux et al. Neurol, 45:555-557, 1995.
Nicoll et al. Ann N Y Acad Sci, 777: 271-275, 1996.
Capruso and Levin. Neurol Clin10: 879-893, 1992.
Dixon et al. Behav Brain Res 70:125-131, 1995.
Pike and Hamm. Exptl Neurol, 147: 55-65, 1997.
Pike and Hamm. Pharmacol Biochem Behav, 57: 785-791, 1997.
Pike and Hamm. J Neurotrauma, 14: 897-905, 1997.
Irwin, S. Psychopharm 13:222-257, 1968.
Beach et al, neurosci Lett 283: 9-12, 2000.
Beach et al., Brian res 905:220-220, 2001.
Pfeifer et al., Science 2002 298:1379.
Nicoll et al, Nature Medicine, Mar. 2003.
Sparks et al. Neurosci Lett 1995; 187:142-144.
Refolo et al Neurobiol 890-899, 2001.
Refolo et al, Soc Neurosci Abst 2001, San Diego, CA, USA.
Cedazo-Minguez et al, Neurosci, 105: 651-661, 2001.
Sparks et al. Neurosci Lett 1995; 187:142-144.
Dean et al, Mol Psychiatry 1996; 1:54-8.
Dean et al, Mol Psychiatry 2002; 7: 1083-91.
Raedler et al, Am J. Psychiatry 160: 118, 2003.
Borda et al J Immunol 2002; 168:3667-74.
Felder et al, Life Sci 2001 8:2605-13.
Bymaster et al, Current Drug Targets- CNS & Neurological Disorders 2002; 1:147-164.
Sullivan et al, Br J Psychiatry 2000; 177: 174-178.
Gould and Manji. Neuroscientist 2002; 8:497-511.
Cotter et al, NeuroReport 9: 1379, 1998.
Casanova MF et al Acta Neuropathol (Berl) 2002 103: 313-20.
Auld et al Prog Neurobiol 2002, 68:209-45.
Poeggeler et al, Brain Res 815: 382-388, 1999.
Chyan et al. J Biolog Chem 274: 21937-21942, 1999.
Bons et al., Alzheimer's Res (1995) 1:83-87.
Mazzoti et al (Proceedings of the Chiral Europe 96 Symp, Spring Innovations, Stockport UK, p 103, 1996.
Krise et al, J Med. Chem. 42: 3094-3100 (1999).
Fassbeder et al, PNAS,98: 5856, 2001.
Sparks et al. Exp Neurol 1994; 126:88-94.
Sparks Nutr Metab Cardiovasc Dis 1997: 7:255-266.
Klausner, Biotechnol 5:779-786, 1987.
Lipman et al, Cytotechnol 8:129-176, 1992.
Rappoport and Ferreira J. Neurochem. 74:125-133 (2000).
Ekinci et al J. Biol. Chem. 274: 30322-30327 (1999).
Sadot et al J.Neurochem. 66:877-880, 1996.
Poirier et al Neuroscience 55: 81-90 (1993).
Cedazo-Minuez et al Neurosci 105: 651-661, 2001.
Gurwitz et al Eur. J. Pharmacol. 267, 21, 1994.
Fisher et al, J. Neural Transm Suppl 62: 189, 2002.
Chen et al, J Neurotrauma, 15: 231-237, 1998.
Dantzer et al. Psychopharmacol. 91:363-368, 1987.
Perio et al Psychopharmacol. 97: 262-268. 1989.
Fisher et al, J. Pharmacol. Exptl. Therap., 257: 392, 1991.
Simons et al Life Sci., 42, 375-383, 1988.
Vincent et al Brain Res., 597, 264-268, 1992.
Schwarz et al Drug Dev. Res., 40, 133-143, 1997.
Volpe et al, Stroke, 20: 1700-1706, 1989.
Bymaster et al. J Pharmacol Exp Ther 267: 16-24, 1993.
Roldan et al Neurosci. Lett. 230: 93-96, 1997.
Kimura et al Brain Res. 834: 6-12, 1999.
Garrido JL et al. (FASEB J 2002; 16:1982.
Bar-Ner Nira
Fisher Abraham
Karton Yishai
Israel Institute for Biological Research
Reiter Stephen E.
LandOfFree
Methods and pharmaceutical compositions for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceutical compositions for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceutical compositions for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643573